Translational Research Working Group developmental pathway for immune response modifiers

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5692-5699

  Cheever, Martin A ^a,b   Schlom, Jeffrey ^a,c   Weiner, Louis M ^a,d   Lyerly, H Kim ^a,e   Disis, Mary L ^a,b   Greenwood, Addison ^a,c   Grad, Oren ^a,f   Nelson, William G ^a,g,h  

^a Translational Research Working Group

^b Fred Hutchinson Cancer Research Center

^c NATIONAL CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e DUKE UNIVERSITY   (United States)

^f Science and Technology Policy Institute   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENILEUKIN DIFTITOX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 7; IMMUNOLOGIC FACTOR;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; COMPUTER PROGRAM; HEALTH CARE ORGANIZATION; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; UNITED STATES;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; ORGANIZATION AND ADMINISTRATION; PROGRAM DEVELOPMENT; SOFTWARE DESIGN; UNITED STATES;

EID: 53249086543     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1266     Document Type: Review

References (20)

1. Hawk ET, Matrisian LM, Nelson WG, et al. Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 2008;14: 5664-71.
2. Mihich E. Combined effects of chemotherapy and immunity against Leukemia L1210 in DBA/2 Mice. Cancer Res 1969;29:848-54.
3. Arlen PM, Madan RA, Hodge JW, Schlom J. Combining vaccines with conventional therapies for cancer. Update Cancer Ther 2007;1:33-9.
4. Arlen PM, GulleyJL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007;27:451-62.
5. Finn OJ. Cancer Immunology. N Engl J Med 2008; 58:2704-15.
6. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;22:357-68.
7. Chen W, Chan AS, Dawson AJ. Liang X, Blazar BR. Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxyucleotides to enhanceTcell and natural killer cell function. Biol Blood Marrow Transplant 2005;11:23-34.
8. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90: 297-339.
9. Irvine KR, Chamberlain RS, Shulman EP, Surman DR. Rosenberg SA, Restifo NIP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-601.
10. Mackall CL, FleisherTA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
11. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6.
12. Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) 2008;233:522-34.
13. Nicolin A, Canti G, Marelli O. Veronese F, Goldin A. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines. Cancer Res 1981; 41:1358-62.
14. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405.
15. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
16. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156: 3151-8.
17. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5: 1289-97.
18. Disis ML, GooleyTA, Rinn K, et al. Generation of T- cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
19. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004;22:1916-25.
20. Limentani S, Dorval T, White S, et al. Phase I doseescalation trial of a recombinant HER2 vaccine in patients with Stage ll/lll HER2+ breast cancer. J Clin Oncol 2005;23:2520.